Physician Rollover Equity Checklist: 25 Questions Before You Roll
Rollover equity is the part of your sale price you take in the buyer's equity instead of cash. Roll only when four terms are in writing. Your units sit in the holdco the next buyer will purchase. You pay the sponsor's price per unit. You hold the sponsor's class, with no participating or accruing preferred ahead of you. Units bought with your rollover proceeds are fully vested at close and are bought back at fair value if you leave. Then size the roll to an amount you could lose entirely without missing a liquidity need.
The 25 questions below test each term. Every worked example uses the same hypothetical platform, so the dollar figures reconcile from section to section.
The base case used in every worked example
All figures in this box are hypothetical. The arithmetic is ours.
| Input | Figure | How it is derived |
|---|---|---|
| Your practice | $2.0M EBITDA, sold at 8x | Inside Sikich's 7 to 9x indicative band for $1M to $3M of EBITDA (see the multiples table below) |
| Purchase price | $16.0M, gross of fees | $2.0M × 8 |
| Cash at close | $12.0M, before tax and fees | 75% of $16.0M |
| Rolled | $4.0M, at the sponsor's unit price | 25% of $16.0M |
| Platform after close | $30M EBITDA, valued at 12x | $360M enterprise value |
| Platform debt | $160M | About 5.3x EBITDA, near the 5.2x 2025 median cited below |
| Holdco equity | $200M | $360M less $160M |
| Ownership of holdco equity | Sponsor $180M (90%), physicians $20M (10%) | Assumed for the example |
| Your stake | 2.0% of all equity, 20% of the physician class | $4.0M ÷ $200M, and $4.0M ÷ $20M |
Unless an example says otherwise, it ignores transaction fees, sponsor fees, taxes, debt paydown and new equity issued after close. Those items reduce real outcomes. This is stake math, not a full returns model.
Where physician rollover equity sits in 2026
| Data point | Figure | What it means for a rollover |
|---|---|---|
| US spending on physician and clinical services, 2024 (CMS National Health Expenditure fact sheet) | $1,109.7 billion, up 8.1%. CMS projects average growth of 5.5% a year from 2025 to 2034 | Platforms are buying into a revenue pool that is still growing |
| Physicians in PE-owned practices, 2024 (AMA Physician Practice Benchmark Survey) | 6.5%, up from about 4.5% in both 2020 and 2022 | More physicians now hold sponsor equity |
| Physicians in PE-owned practices whose practice was acquired in the prior five years, 2024 (AMA) | 38%, compared with 10.0% in hospital-owned practices | Many PE rollover holders are still mid-hold |
| Physicians whose practice was acquired before 2015, 2024 (AMA) | 17.1% in PE-owned practices, 47.2% in hospital-owned | Few PE-era rollovers have been through a full exit cycle |
| PE-backed US healthcare deals tracked in 2025 (PESP, PitchBook and LevinPro HC data) | 1,029 deals: 664 add-ons, 214 growth investments and 151 buyouts, across 420 platforms | Most sellers roll into an existing platform, not a new one |
| Dental deals that were add-ons, 2025 (PESP) | 95% of 149 dental deals | Most dental sellers roll at a platform's current mark |
| Physician groups as a share of global provider transactions (Bain, Global Healthcare PE Report 2026) | 28% in 2021, 23% in 2025 | Buyers are more selective about which groups they back |
| Earnout use by US PE buyers in SRS Acquiom's private-target deal dataset (SRS Acquiom, 2026 earnout study) | 24% of 2025 deals, 13% across 2014 to 2022 | More of the price now sits at risk after close |
| Entry leverage, median PE-backed US healthcare services buyout, 2025 (PitchBook data reported by Sikich, Q3 2026 update) | 5.2x EBITDA | Debt sits ahead of every equity class |
PESP describes its 2025 count as likely an underestimate. The add-on share is the figure that matters most. A physician who sells into a platform three years into its hold buys units at today's mark, not at the sponsor's entry price.
How much to roll: decision table
The rollover percentage is an investment decision. Size it to your situation before you look at the sponsor's model.
| Your situation | Lean toward | Why |
|---|---|---|
| Platform is early in its hold and you roll at the sponsor's unit price | Larger roll | You share the full entry-to-exit growth |
| Platform is late in its hold | Smaller roll, or a lower unit price | Growth already captured is priced into your units |
| You plan to practice through the likely exit | Larger roll, if questions 3 and 13 come back clean | You are present to drive growth and hold to the sale |
| You plan to retire or step back within a few years | Smaller roll | The exit may come after you leave, and leaver terms then set your price |
| The deal also carries an earnout | Smaller roll | Both depend on the same platform's performance |
| Sponsor holds participating or accruing preferred | Smaller roll, or renegotiate the class | The waterfall below shows why |
| Practice debt, real estate or estate needs call for cash | Roll only what you could lose entirely | Rollover units are illiquid until the sponsor exits |
Questions 1 to 6: Holdco, opco or MSO
The issuing entity decides what your units are a claim on.
| # | Question | What it means for you | Document or proof | Red flag |
|---|---|---|---|---|
| 1 | Which entity issues my units: holdco, MSO or practice opco? | Holdco units share in platform value. Opco units track one site and rarely have a buyer of their own. | Rollover or contribution agreement naming the issuer | Units issued by an entity with no exit path |
| 2 | How many layers sit between my units and the exit buyer? | Each layer can carry its own debt, preferred and fees | Structure chart down to your class | A topco or midco you cannot see into |
| 3 | Is my class the same class the sponsor holds? | Class parity is the strongest protection a minority holder has | Cap table and LLC agreement class definitions | Sponsor in preferred, physicians in common or "Class B" |
| 4 | How much debt sits ahead of my units today, and what can be added? | Every dollar of debt is paid before equity at exit | Credit agreement summary and incremental debt basket | No access to debt terms |
| 5 | Has your attorney reviewed the ownership and governance structure under state rules on who may own a medical practice? | A structure that has to be reworked later moves on someone else's timeline | Written structure review and the MSA | No written review, or a physician holding roles on both sides of the MSA with no review |
| 6 | Could this deal, or a later exit, need a regulatory filing that affects timing? | Filings can set the earliest closing date | Written filing plan with target dates | Closing date set before the filing question is answered |
Worked example, debt ahead of equity (hypothetical, our arithmetic). The base-case platform carries $160M of debt on $30M of EBITDA, about 5.3x. That sits near the 5.2x 2025 median entry leverage for PE-backed US healthcare services buyouts in PitchBook data reported by Sikich. The same data put implied EBITDA for that median buyout at roughly $33 million, so a $30M platform is a realistic size. At exit, $160M is repaid before any unit holder sees a dollar. A sponsor that has paid down debt will carry less. One that funded add-ons with new borrowing will carry more, as the late-entry example below shows. Ask for the actual figure under question 4.
The legal areas behind questions 5 and 6
Four areas can change where your units sit or when the deal closes. State rules on who may own a medical practice can decide whether the economic rollover sits in the MSO or its parent. Federal referral and self-referral rules (HHS OIG overview) can matter when physicians who refer into the platform hold its equity. Federal and state transaction notice rules (FTC premerger notification program) can affect the closing date for this deal and for the exit. Offering units to physicians also raises securities questions. Have your attorney review each area against this deal before a closing date is set. Our healthcare compliance due diligence guide and healthcare M&A process guide show where those reviews fall in the timeline. The management services organizations guide covers MSO structure.
Questions 7 to 12: Rollover valuation and second bite math
Your exit buyer is most likely another sponsor. Bain & Company's Global Healthcare Private Equity Report 2026 expected more than 150 sponsor-to-sponsor healthcare deals globally in 2025, worth more than $120 billion. North America had 26 healthcare PE transactions above $1 billion as of November 2025, compared with 14 in all of 2024, and more than 70% of them were sponsor-to-sponsor sales.
Strategic buyers are the other path. Bain's physician group analysis cites Cardinal Health's original acquisition of GI Alliance from a group of physician owners and Apollo Global Management, Cencora's acquisition of Retina Consultants of America from Webster Equity Partners, and the acquisition of the urology platform Solaris Health from Lee Equity Partners by Cardinal Health's GI Alliance. A strategic exit does not guarantee physician holders an all-cash payout. Question 11 decides whether you can be asked to roll again.
| # | Question | What it means for you | Document or proof | Red flag |
|---|---|---|---|---|
| 7 | What price per unit am I rolling at, and is it the sponsor's price? | Paying more per unit than the sponsor transfers value to the sponsor on day one | Funds flow and cap table at close | Physicians roll at a higher price or after fees are deducted |
| 8 | What EV/EBITDA multiple sets the holdco unit price, compared with the multiple paid for my practice? | Selling at 8x and buying units priced at 12x means each rolled dollar buys less of the platform | Holdco valuation memo or sponsor's purchase price | Holdco valuation not disclosed |
| 9 | Is my rollover percentage negotiable, and can I roll less? | Rollover is an investment decision. It should not be a default closing condition. | LOI rollover term | Percentage set or raised after the LOI |
| 10 | What exit multiple, hold period and add-on pace does the sponsor's model assume? | Your second bite is the sponsor's base case | Returns model summary | Second bite depends on multiple expansion alone |
| 11 | What happens to my units if the platform sells to another sponsor or a strategic buyer? | A forced re-roll defers your second payday | Exit and transfer provisions | Buyer can require a re-roll at its election |
| 12 | What sponsor fees are paid out of holdco before equity? | Monitoring and transaction fees cut equity value | Sponsor management agreement | Uncapped fees senior to equity |
The multiple gap, by source
Second bite math starts with the gap between what the platform pays for your practice and what the next buyer pays for the platform. Each row measures a different population and period. Read them separately, not as one series.
| Source and population | As of | Figure |
|---|---|---|
| Sikich Q3 2026 update, indicative physician practice EV/EBITDA by EBITDA size | 2026 | 5 to 7x below $1M, 7 to 9x at $1M to $3M, 9 to 11x at $3M to $5M, 11 to 13x above $5M |
| Same Sikich update, specialty platforms compared with add-on practices | 2026 | Platforms "command a four- to eight-turn premium over add-on practices" |
| Same Sikich update, dental (DSOs), indicative | 2026 | Platforms 9 to 11x, add-ons 5 to 8x, practices 5 to 9x |
| PitchBook data reported by Sikich, median PE-backed US healthcare services buyout | 2025 | 13.6x EBITDA, compared with 13.5x in 2024 |
| BuckheadFMV, US healthcare services control deals with disclosed prices, minority and physician-syndication stakes excluded | Jan 2023 to Oct 2026 | Median 9.6x EBITDA across the 68 of 187 deals with positive reported EBITDA. Deals above $200M at a median 11.2x |
| Axia Growth, closed healthcare-sector small-business sales | Data as of Oct 28, 2026 | Median 5.1x EBITDA at $2M to $3M of EBITDA (13 sales), 12.9x at $10M+ (17 sales) |
The direction is the same in every dataset. Value per dollar of EBITDA rises with scale. That premium funds the roll-up thesis and produces your second bite. It also works against you on question 8.
Worked example, question 8 (hypothetical, our arithmetic). Your $2.0M EBITDA practice sells at 8x. You roll $4.0M into the base-case platform. Enterprise value is EBITDA times the multiple. Equity value is enterprise value less debt. Your stake is rolled dollars divided by equity value.
| Holdco EV/EBITDA multiple | Enterprise value | Less debt | Equity value | Your $4.0M buys |
|---|---|---|---|---|
| 8x | $240M | $160M | $80M | 5.0% |
| 12x | $360M | $160M | $200M | 2.0% |
At the 12x mark, the same $4.0M buys 60% less of the platform. Debt widens the gap. With no debt, the stake would fall by one third (1.67% to 1.11%). With $160M of debt ahead of equity, it falls by more than half. Ask what multiple sets your unit price, and get the debt figure behind it.
Worked example, joining late in the hold (hypothetical, our arithmetic). The sponsor bought the base-case platform with $200M of equity. Three years later EBITDA is $45M, the platform is marked at 13x ($585M enterprise value) and add-on borrowing has lifted debt to $200M. Current equity is $385M, and that is the mark you roll at. Two years later the platform exits at 13x on $55M of EBITDA: $715M enterprise value, $200M of debt, $515M of equity. The example treats your $4.0M as too small to move the totals.
| Holder | Equity value when units were bought | Equity value at exit | Multiple on equity |
|---|---|---|---|
| Sponsor, entered in year 0 | $200M | $515M | About 2.58x |
| You, rolled in year 3 | $385M mark | $515M | 1.34x |
Your $4.0M becomes about $5.35M. The sponsor earned most of its return before you arrived. That is the case for a lower unit price, a smaller roll or both.
Worked example, second bite (hypothetical, our arithmetic). Base case: $16.0M price, $12.0M cash, $4.0M rolled for 2.0% of $200M of holdco equity. No preference ahead of your units and no re-roll at exit.
| Holdco equity at exit | Cash at close | Second bite (2.0% of exit equity) | Total proceeds | Effective multiple on $2.0M EBITDA |
|---|---|---|---|---|
| Doubles to $400M over five years | $12.0M | $8.0M | $20.0M | 10.0x |
| Flat at $200M | $12.0M | $4.0M | $16.0M | 8.0x |
| Halves to $100M | $12.0M | $2.0M | $14.0M | 7.0x |
For reference, FOCUS Investment Banking's 2026 dermatology benchmarks report that platform-ready dermatology practices, typically $5M or more of EBITDA, often receive 70% or more in cash at close with meaningful rollover equity. FOCUS counts more than 35 sponsor-backed dermatology platforms operating nationally in 2026. That covers one specialty at platform scale. Smaller add-on practices often see different splits. Test the growth your second bite needs against the sponsor's model in question 10, and run your own cases in the rollover equity calculator.
Questions 13 to 18: Liquidation preferences, drag-along and tag-along
| # | Question | What it means for you | Document or proof | Red flag |
|---|---|---|---|---|
| 13 | What preference does the sponsor hold: multiple, participation, accruing return? | Preference terms decide who is paid first when exit value disappoints | Waterfall section of the LLC agreement | Participating or accruing preferred ahead of rolled common |
| 14 | Can new debt or preferred be issued ahead of me without my vote? | Senior issuance cuts your recovery | Protective provisions | Sponsor-only board vote on senior securities |
| 15 | Do I have preemptive rights in follow-on rounds? | Add-on financing at a low price dilutes holders who cannot participate | Preemptive rights clause | Rights limited to "accredited sponsor affiliates" |
| 16 | What triggers the drag-along, and what protects my price and consideration? | A drag forces you to sell on the sponsor's terms | Drag clause with same price and same form of consideration | Sponsor takes cash while physicians take buyer stock |
| 17 | Can I tag along pro rata when the sponsor sells part of its stake? | Partial sponsor exits otherwise leave you behind | Tag-along clause | Tag applies only on a full change of control |
| 18 | Are my exit reps, indemnity and escrow several, pro rata and capped at my proceeds? | Joint liability puts your proceeds behind other sellers' breaches | Drag clause indemnity terms | Joint and several liability |
Preferences only matter in the downside, which is when a minority holder needs protection most.
Worked example, waterfall (hypothetical, our arithmetic). Base case: sponsor $180M (90%), physicians $20M (10%) in common, your $4.0M is 2.0% of all equity and 20% of the physician class. Exit equity is holdco value after debt is repaid.
- Pari passu. One class for everyone. You receive 2% of exit equity.
- 1x non-participating preferred. The sponsor takes the greater of its $180M preference (capped at exit equity) or 90% of exit equity as converted. If it takes the preference, physician common splits the remainder and you receive 20% of it.
- 1x preferred plus 8% accrual for five years. The claim compounds to $180M × 1.08^5, about $264.5M. Same conversion test.
- 1x participating preferred. The sponsor takes $180M first, then 90% of what remains. You receive 2% of the remainder.
| Exit equity value | Pari passu common | 1x non-participating preferred | 1x preferred plus 8% accrual | 1x participating preferred |
|---|---|---|---|---|
| $120M | $2.4M | $0 (the $180M claim absorbs all $120M) | $0 (the $264.5M claim absorbs all $120M) | $0 (the $180M claim absorbs all $120M) |
| $250M | $5.0M | $5.0M (sponsor converts: $225M beats $180M) | $0 (the $264.5M claim absorbs all $250M) | $1.4M (2% of the $70M remainder) |
| $400M | $8.0M | $8.0M (sponsor converts: $360M beats $180M) | $8.0M (sponsor converts: $360M beats $264.5M) | $4.4M (2% of the $220M remainder) |
The same $4.0M rollover returns anything from zero to 2.0x, depending on terms the LOI rarely spells out. Under 1x non-participating preferred, the sponsor converts above $200M of exit equity. With the 8% accrual, conversion only pays above about $294M. Between $264.5M and $294M, physician common shares only what is left after the sponsor's $264.5M claim. Model your rollover at three exit values before you accept any preferred class above your units.
See the healthcare capital stack chart.
On question 18, earnouts change your exposure at the next exit too. In SRS Acquiom's 2026 earnout study, US PE buyers used earnouts in 24% of 2025 deals in its dataset, compared with 13% across 2014 to 2022. If a drag sale includes an earnout, the drag clause should give you the same contingent terms as the sponsor and a pro rata share of any payout.
Questions 19 to 25: Tax, vesting, governance and information rights
Two kinds of equity show up in physician deals, and they should never be confused. Rollover units are bought with your own sale proceeds. Incentive units, often structured as profits interests, are granted for future performance and share only in growth above the value at grant. Incentive units commonly vest over time and carry their own tax elections with short deadlines, which your CPA should handle at grant. Rollover units should not vest at all.
| # | Question | What it means for you | Document or proof | Red flag |
|---|---|---|---|---|
| 19 | Which part of my proceeds is taxable at close, and which is deferred? | Asset or equity sale, basis, price allocation, cash paid alongside the units, liabilities assumed and the order of closing steps all decide what is taxed now | Tax structure memo and step plan modeled by your CPA | No written step plan, or one your CPA has not modeled |
| 20 | Is the holdco a partnership or a corporation, and does it make tax distributions on income allocated to me? | Pass-through holdcos allocate taxable income with or without cash | Tax distribution clause | Distributions at board discretion |
| 21 | Are my purchased rollover units fully vested at close, and are any incentive units documented separately? | You bought the rollover with your own proceeds. Time vesting belongs only on granted incentive units. | Rollover agreement and any separate incentive grant | Rollover units subject to time vesting or forfeiture |
| 22 | What happens to my units if I retire, become disabled, leave or am terminated? | Call rights set the price you receive on departure | Leaver and repurchase provisions | Call at cost or "lower of cost or fair value" for any departure |
| 23 | What board seat, observer seat or consent rights do physician holders get? | Minority consent blocks related-party fees and class changes | Board composition and supermajority list | No physician vote on amendments that change unit rights |
| 24 | What financials do I receive, and do I get notice of any exit? | You cannot price a drag or a re-roll you were not told about | Information rights clause | Information "as the board determines" |
| 25 | Does the agreement include a waterfall exhibit with worked examples by class? | Ambiguous class language is settled by whoever holds the cash | Waterfall exhibit | Payout clauses that say "units" without naming the class |
Worked example, question 22 (hypothetical, our arithmetic). Three years after close, holdco equity is marked at $300M, so your 2.0% stake is worth $6.0M, a 1.5x gain on $4.0M. You leave the practice. A call at fair value pays $6.0M. A call at "lower of cost or fair value" pays $4.0M. A call at cost after a for-cause termination also pays $4.0M. The leaver clause is worth $2.0M in this example, and the sponsor drafts it. Negotiate fair value for retirement, death and disability, and a narrow, objective definition of "cause."
Questions 24 and 25 cost the sponsor little to grant. Written notice of any sale process and a waterfall exhibit that names your class leave no room to dispute which class your payout follows.
Check the sponsor before you hand it your equity
Run reverse due diligence on the sponsor with the same rigor it applies to your practice.
| Check | Where | What you are looking for |
|---|---|---|
| Past rollover outcomes | Two or three physicians who rolled into the sponsor's prior platforms, chosen by you, not the sponsor | What they received at exit, in what form and when, whether anyone was re-rolled or called at cost, and whether they would roll again |
| Capital raised by the platform and its parents | SEC EDGAR full-text search, searching entity names for Form D notices | Equity raised since entry, which tells you how many new holders now share the cap table |
| The banker or placement agent on the deal | FINRA BrokerCheck | Registration status and any disclosure history |
| Platform age and add-on pace | Sponsor press releases and the returns model from question 10 | Whether you are entering early in the hold or at a late mark |
Rollover negotiating positions: ask, fallback, walk away
Price, rollover percentage and class are set in the LOI and get much harder to move once you sign exclusivity. Drag, leaver, fee and information terms are negotiated in the LLC agreement after the LOI, but put your positions on them in the LOI so they are on the table early. Dollar figures come from the base-case examples above.
| Term (question) | Ask for | Acceptable fallback | Walk away if | What it was worth in our examples |
|---|---|---|---|---|
| Unit price (7, 8) | The sponsor's price per unit | A discount to the current mark if the platform is past year two | Physicians pay a higher price or roll after fees | Year-three entry: 1.34x on equity against the sponsor's 2.58x |
| Rollover size (9) | The percentage you sized in the decision table | A smaller roll in exchange for more cash at close | The percentage rises after the LOI | 25% of $16.0M is $4.0M of illiquid units |
| Class (3, 13) | Same class as the sponsor, pari passu | 1x non-participating preferred ahead of you | Participating or accruing preferred with no cap | At a $250M exit: $5.0M pari passu, $1.4M participating, $0 accruing |
| Sponsor fees (12) | Fees capped and paid after equity | Capped fees senior to equity | Uncapped fees senior to equity | Every fee dollar comes out of exit equity before your 2% |
| Drag and tag (16, 17) | Same price, same form of consideration, pro rata tag on any sale | Tag on sales above a set share of the sponsor's stake | Sponsor takes cash while physicians take buyer stock | Your full second bite rides on this clause |
| Exit indemnity (18) | Several, pro rata, capped at your proceeds | Cap at a fixed share of your proceeds | Joint and several liability | An $8.0M second bite exposed to other sellers' breaches |
| Vesting and leaver (21, 22) | Fully vested rollover units, fair value call for any departure | Fair value for retirement, death and disability, narrow "cause" | Time vesting on rollover units, or call at cost for any departure | $2.0M gap on units marked at $6.0M |
| Information and waterfall (24, 25) | Quarterly financials, written notice of any sale, waterfall exhibit by class | Annual financials plus notice and the exhibit | Information "as the board determines" | Without it you cannot check any figure above |
One $4.0M roll, seven outcomes: stress test before you sign
The worked examples change one term at a time. Side by side, the same $4.0M rollover from the $16.0M sale ranges from nothing to $8.0M. Practice performance is identical in every row. Only terms and timing change. All figures are hypothetical and use the base case.
| Scenario | Terms that drive it | What $4.0M returns | Multiple on rolled dollars |
|---|---|---|---|
| Best case | Sponsor's unit price, same class, holdco equity doubles to $400M | $8.0M | 2.0x |
| Late entry | Rolled in year three at the platform's $385M mark, exit two years later at $515M | About $5.35M | 1.34x |
| Flat exit | Sponsor's unit price, same class, holdco equity flat at $200M | $4.0M | 1.0x |
| Early departure | Leave in year three with units marked at $6.0M, call at cost | $4.0M | 1.0x |
| Down exit | Sponsor's unit price, same class, holdco equity halves to $100M | $2.0M | 0.5x |
| Participating preferred | 1x participating preferred ahead of common, exit equity $250M | $1.4M | 0.35x |
| Accruing preferred | 1x preferred plus 8% accrual ahead of common, exit equity $250M | $0 | 0x |
How to use it before the LOI is final:
- Rebuild the table with the sponsor's numbers. Replace our unit price, debt, mark and preference terms with the figures from questions 4, 7, 8 and 13.
- Add your own departure row. If you expect to step back before the likely exit, price the leaver clause from question 22 at your planned date.
- Check the worst row against your cash needs. Cash at close here is $12.0M before tax and fees. If the $0 row would leave practice debt, real estate or estate needs unfunded, cut the roll before you negotiate anything else.
- Trade terms, not just percentage. Moving from accruing preferred to the same class lifts the $250M exit row from $0 to $5.0M (2% of $250M). That is worth more than most changes to the rollover percentage.
- Send the table to your CPA with the step plan. Ask which rows the tax treatment changes, and by how much after tax.
Scoring rule: count the answers you can prove with a document
Score one point for each question you can answer today with a signed or draft document. Verbal answers score zero.
| Score | Status | Next step |
|---|---|---|
| 21 to 25 | Documented | Negotiate economics |
| 14 to 20 | Partial | Request the missing documents before definitive agreements |
| 13 or fewer | Blind | Hold the LOI open until questions 1, 3, 7, 13 and 25 are documented |
A red flag on question 3, 13, 16, 21 or 25 blocks the deal whatever the score.
30/60/90-day order of work before you sign
Days 1 to 30. Get the structure chart, cap table, draft LLC agreement, holdco valuation and current debt figure (questions 1 to 4, 7 and 8). Run the waterfall at three exit values, and the late-entry math if the platform is past year two. Check the LOI against the LOI and term sheet red flags checklist. Start the sponsor checks above.
Days 31 to 60. Negotiate class parity, preference terms, fee caps, drag protections, tag rights and preemptive rights (questions 9 to 18). Commission the tax memo and step plan. Get the written regulatory view from questions 5 and 6, then set the closing date against it.
Days 61 to 90. Close out vesting, leaver terms, governance, information rights and the waterfall exhibit (questions 19 to 25). Confirm the final documents match the deal structure you priced. Then score again.
Questions owners ask about rollover equity
Should physicians roll equity at the holdco or the practice level?
Holdco in most platform deals. Holdco units share in the value of the whole platform, including add-ons bought at lower multiples, and the next buyer purchases them at exit. Practice-level or opco equity tracks one location, often has no buyer of its own and can be diluted by intercompany fees. Where the clinical entity stays physician-owned, the economic rollover usually sits in the MSO or its parent.
How much of the price is usually rolled?
No single benchmark covers every specialty. For dermatology, FOCUS Investment Banking's 2026 benchmarks report that platform-ready practices, typically $5M or more of EBITDA, often receive 70% or more of the price in cash at close with meaningful rollover equity. Smaller add-on practices and other specialties see different splits. Size your roll to an amount you could lose entirely and still meet your personal liquidity needs.
Is rollover equity taxed at closing?
Not all of it. How much is taxed at close depends on how the deal is structured. Have your CPA and attorney model the step plan before the LOI is signed.
How do I estimate my second bite?
Multiply your share of holdco equity by holdco equity value at exit, after debt, fees and any preference ahead of your class. Hypothetical, our arithmetic: $4.0M rolled at the sponsor's unit price buys 2% of $200M of holdco equity. If equity doubles to $400M, your second bite is $8.0M. If a preference sits ahead of your class and equity value falls, the same units can return nothing. Run three exit cases, not one.
What changes if I join a platform late in its hold?
You buy units at the platform's current mark, so the growth the sponsor captured before you arrived is not yours. In our hypothetical example, a physician who rolls in year three earns 1.34x on the remaining growth while the sponsor earns about 2.58x on the same exit. Push for a lower unit price, a smaller roll or both.
Sources
- CMS, National Health Expenditure Fact Sheet, 2024 data and 2025 to 2034 projections
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook (citing PitchBook)
- BuckheadFMV, Healthcare Services M&A Valuation Multiples 2023 to 2026, 187 control transactions January 2023 to October 2026
- Axia Growth, Physician Practice Management and MSOs, data as of October 28, 2026
- Bain & Company, Global Healthcare Private Equity Report 2026, press release on 2025 data
- Bain & Company, New Models of Value Creation for Physician Groups, 2026
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends, 2025 data
- HHS OIG, A Roadmap for New Physicians: Fraud and Abuse Laws
- FTC, Premerger Notification Program
- SEC EDGAR full-text search
- FINRA BrokerCheck